Office of Biotechnology Activities; Office of Science Policy; Office of the Director; Notice of a Meeting of the NIH Blue Ribbon Panel, 2549 [2010-730]
Download as PDF
Federal Register / Vol. 75, No. 10 / Friday, January 15, 2010 / Notices
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Health Resources and Services
Administration
Health Center Program
AGENCY: Health Resources and Services
Administration, HHS
ACTION: Notice of Noncompetitive
Replacement Award to Regional Health
Care Affiliates.
SUMMARY: The Health Resources and
Services Administration (HRSA) will be
transferring Health Center Program
(section 330 of the Public Health Service
Act) funds originally awarded to Trover
Health System to Regional Health Care
Affiliates to ensure the provision of
critical primary health care services to
underserved populations in Webster
and McLean Counties, Kentucky.
SUPPLEMENTARY INFORMATION:
Former Grantee of Record: Trover
Health System.
Original Period of Grant Support:
June 1, 2009 to February 28, 2011.
Replacement awardee: Regional
Health Care Affiliates.
Amount of Replacement Award:
$17,000.
Period of Replacement Award: The
period of support for the replacement
award is September 1, 2009, to February
28, 2011.
jlentini on DSKJ8SOYB1PROD with NOTICES
Authority: Section 330 of the Public
Health Service Act, 42 U.S.C. 245b.
CFDA Number: 93.224.
Justification For The Exception To
Competition: Under the original grant
application approved by HRSA,
Regional Health Care Affiliates (RHCA)
was identified as the provider of health
care services on behalf of the Trover
Health System, while Trover Health
System was to serve in an
administrative capacity for the grant.
After the award was issued, Trover
Health System and RHCA notified
HRSA that RHCA’s organizational
structure had changed to enable it to
carry out both administrative and
programmatic requirements. The two
parties requested that full responsibility
for the grant be transferred from Trover
Health System to RHCA. RHCA
provided documentation that it meets
Section 330 statutory and regulatory
requirements as well as applicable grant
management requirements.
Regional Health Care Affiliates will
directly initiate primary health care
services in Webster and McLean
Counties to the more than 5,250 low
income, underserved and uninsured
individuals in the original service area,
Webster and McLean Counties, KY, as
VerDate Nov<24>2008
17:34 Jan 14, 2010
Jkt 220001
had been proposed in funded grant
application.
Regional Health Care Affiliates can
provide primary health care services
immediately, is located in the same
geographical area where the Trover
Health System’s primary health care
services have been provided, and will
be able to provide continuity of care to
patients of the former grantee.
This underserved target population
has an immediate need for vital primary
health care services and would be
negatively impacted by any delay
caused by a competition. As a result, in
order to ensure that critical primary
health care services are available to the
original target population in a timely
manner, this replacement award will
not be competed.
FOR FURTHER INFORMATION CONTACT:
Marquita Cullom-Stott via email at
MCullom-Stott@hrsa.gov or 301–594–
4300.
Dated: January 11, 2010.
Mary K. Wakefield,
Administrator.
BILLING CODE 4165–15–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Office of Biotechnology Activities;
Office of Science Policy; Office of the
Director; Notice of a Meeting of the NIH
Blue Ribbon Panel
The purpose of this notice is to inform
the public about a meeting of the NIH
Blue Ribbon Panel to Advise on the Risk
Assessment of the National Emerging
Infectious Diseases Laboratories at
Boston University Medical Center.
There will be a meeting of the NIH
Blue Ribbon Panel to advise on the Risk
Assessment of the National Emerging
Infectious Diseases Laboratories (NEIDL)
at Boston University Medical Center.
The meeting will be held on Friday,
February 12, 2010, at the Hyatt Regency
Bethesda Hotel, located at 7400
Wisconsin Avenue, Bethesda, Maryland
20814, from approximately 8:30 a.m. to
2 p.m. This meeting is the second in a
series of public meetings with the
National Research Council to review the
ongoing supplementary risk assessment
study.
Sign up for public comment will
begin at approximately 8 a.m. In the
event that time does not allow for all
those interested in presenting oral
comments, anyone may file written
comments using the following address
below.
Fmt 4703
Sfmt 4703
Dated: January 11, 2010.
Kelly R. Fennington,
Special Assistant to the Director, Office of
Biotechnology Activities, National Institutes
of Health.
[FR Doc. 2010–730 Filed 1–14–10; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
[Docket No. FDA–2009–N–0604]
Clinical Accuracy Requirements for
Point of Care Blood Glucose Meters;
Public Meeting; Request for Comments
AGENCY:
Food and Drug Administration,
HHS.
National Institutes of Health
Frm 00075
An agenda and slides for the meeting
can be obtained prior to the meeting by
connecting to https://
nihblueribbonpanel-bumcneidl.od.nih.gov/. For additional
information concerning this meeting,
contact Ms. Laurie Lewallen, Advisory
Committee Coordinator, Office of
Biotechnology Activities, Office of
Science Policy, Office of the Director,
National Institutes of Health, 6705
Rockledge Drive, Room 750, Bethesda,
MD 20892–7985; telephone 301–496–
9838; e-mail lewallenl@od.nih.gov.
Food and Drug Administration
[FR Doc. 2010–673 Filed 1–14–10; 8:45 am]
PO 00000
2549
ACTION: Notice of public meeting;
request for comments.
The Food and Drug Administration
(FDA) is announcing a public meeting
entitled: Clinical Accuracy
Requirements for Point of Care Blood
Glucose Meters. The purpose of the
public meeting is to discuss the clinical
accuracy requirements of blood glucose
meters and other topics related to their
use in point of care settings.
Dates and Times: The public meeting
will be held on March 16, 2010, from 9
a.m. to 5 p.m. and on March 17, 2010,
from 9 a.m. to 3:40 p.m.
Location: The public meeting will be
held at the Hilton Hotel in Gaithersburg,
MD, 620 Perry Pkwy., Gaithersburg, MD
20877. For directions, please refer to the
meeting Web page at https://
www.fda.gov/MedicalDevices/News
Events/WorkshopsConferences/
ucm187406.htm.
Contact Person: Arleen Pinkos, Food
and Drug Administration, 10903 New
Hampshire Ave., Bldg. 66, rm. 5618,
Silver Spring, MD 20993, 301–796–
6152, FAX: 301–847–8573, e-mail:
Arleen.Pinkos@fda.hhs.gov.
Registration: Persons interested in
attending the meeting must register by
February 15, 2010. If you wish to attend
this public meeting, you must register
E:\FR\FM\15JAN1.SGM
15JAN1
Agencies
[Federal Register Volume 75, Number 10 (Friday, January 15, 2010)]
[Notices]
[Page 2549]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2010-730]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Office of Biotechnology Activities; Office of Science Policy;
Office of the Director; Notice of a Meeting of the NIH Blue Ribbon
Panel
The purpose of this notice is to inform the public about a meeting
of the NIH Blue Ribbon Panel to Advise on the Risk Assessment of the
National Emerging Infectious Diseases Laboratories at Boston University
Medical Center.
There will be a meeting of the NIH Blue Ribbon Panel to advise on
the Risk Assessment of the National Emerging Infectious Diseases
Laboratories (NEIDL) at Boston University Medical Center. The meeting
will be held on Friday, February 12, 2010, at the Hyatt Regency
Bethesda Hotel, located at 7400 Wisconsin Avenue, Bethesda, Maryland
20814, from approximately 8:30 a.m. to 2 p.m. This meeting is the
second in a series of public meetings with the National Research
Council to review the ongoing supplementary risk assessment study.
Sign up for public comment will begin at approximately 8 a.m. In
the event that time does not allow for all those interested in
presenting oral comments, anyone may file written comments using the
following address below.
An agenda and slides for the meeting can be obtained prior to the
meeting by connecting to https://nihblueribbonpanel-bumc-neidl.od.nih.gov/. For additional information concerning this meeting,
contact Ms. Laurie Lewallen, Advisory Committee Coordinator, Office of
Biotechnology Activities, Office of Science Policy, Office of the
Director, National Institutes of Health, 6705 Rockledge Drive, Room
750, Bethesda, MD 20892-7985; telephone 301-496-9838; e-mail
lewallenl@od.nih.gov.
Dated: January 11, 2010.
Kelly R. Fennington,
Special Assistant to the Director, Office of Biotechnology Activities,
National Institutes of Health.
[FR Doc. 2010-730 Filed 1-14-10; 8:45 am]
BILLING CODE 4140-01-P